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Diarrhea is defined as the passage of three or more loose or watery stools in a 24 h period, a loose stool being one that would take the shape of container [1]. More than 
90% of acute diarrhea is due to infectious agents [2]. Most of the 
deaths from acute infectious diarrhea result from excessive fluid 
and electrolyte losses that result in dehydration and acidosis; thus, 
the majority of times, deaths are avoidable as long as fluid and 
electrolyte losses are replaced properly.
Although the use of oral rehydration therapy (ORT) has 
achieved a dramatic reduction in both morbidity and mortality in 
diarrhea, rehydration has little effect on stool volume or frequency. 
As oral rehydration solution (ORS) per se cannot be the ultimate 
management of diarrhea, the World Health Organization (WHO) 
has recommended the drug treatment should be added as long 
as the drug used has proven safety and efficacy in the pediatric 
population [3]. Racecadotril is a specific enkephalinase inhibitor 
that exhibits intestinal antisecretory activity not only in animals 
but also in humans [4]. Various preclinical and clinical trials on 
racecadotril have established it to be a safe and potent antisecretory 
agent for use in children with diarrhea [5] and the drug controller 
general of India has approved it as antidiarrheal on 10-10-2001 [6].
However, the efficacy and safety of racecadotril in Indian 
children have not been studied extensively. Hence, this study was 
planned to evaluate the efficacy of the drug in the management 
of acute diarrhea in children in a tertiary care hospital with a 
diarrhea treatment and training unit.
METHODS
This was a randomized controlled single center trial. Patients 
with acute watery diarrhea aged between 3 months to 5 years 
with the duration of diarrhea of fewer than 7 days were selected 
for the study. We could not classify the etiology of diarrhea due 
to limited diagnostic facilities. The presence of watery diarrhea 
was confirmed by gross examination of stool before inclusion 
of patients for the study. Subjects were excluded if they had 
persistent vomiting >3 episodes/h, severe dehydration, or any 
serious concomitant illness including HIV seropositive status and 
severe malnutrition, blood in stool, received an antibiotic or any 
antidiarrheal drug within the preceding 48 h.
The study protocol was approved by the institutional ethical 
committee. Parents were explained about the study in the language 
they understand best, and a proper informed consent was taken 
from them. A detailed history was obtained from the parents 
of each of the admitted child with acute watery diarrhea and 
recorded as per the pro forma designed for this study. A standard 
physical examination including assessment of dehydration and a 
basal blood and stool examination was performed.
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Intervention
Simple random sampling was used to randomize the subjects into 
two groups (study and control) by computer-generated numbers. 
All patients from both the groups were given standard WHO-ORS 
depending on their hydration status and oral zinc. A uniform dose 
of 20 mg of elemental zinc was given to all children in both the 
groups during the period of diarrhea and for 7 days after cessation 
of diarrhea as per the recommendations of the IAP national task 
force for the use of zinc in diarrhea [7]. Children in study group 
also received racecadotril at a dose of 1.5 mg/kg/day 8 hourly by 
mixing it with plain water. In addition to ORS, all the subjects 
were given breastfeeding, milk and soft food, as appropriate to 
their age, to provide a daily calorie intake of 100-120 Kcal/kg 
(excluding the calories from glucose in ORS), in accordance with 
WHO recommendations that diet be maintained during treatment 
of diarrhea to prevent nutritional disturbance.
The patients were not given any other medications apart from 
these, and the treatment was given for 5 days or until the patient 
recovered (whichever was earlier). The patient was considered to 
have recovered if he/she had any one of these, (1) <2 stools/day 
for two consecutive days, (2) two consecutive formed stools, 
(3)  not passed stools for 12 h.
Outcomes
The primary efficacy criteria were stool frequency during first 
48 h because the fluid loss and risk of dehydration are maximal 
during this period. The secondary efficacy criteria were the total 
volume of ORS consumed until the cure of diarrhea and time 
taken for a cure.
Tolerability was assessed during each clinical evaluation, and 
all adverse effects were recorded. Clinical symptoms such as 
fever, vomiting, and abdominal distension were assessed every 
4 h. Abdominal distension was assessed by taking abdominal 
girth at the level of the umbilicus. Serum potassium levels were 
measured 24 h after starting racecadotril, and ECG was taken if 
serum potassium levels were low or if the patient had any clinical 
signs of hypokalemia such as hypotonia, abdominal distension, 
weakness, and easy fatigability.
Statistical Analysis
Primary and secondary outcomes (continuous variables) were 
compared between the groups by unpaired t-test. The percentage 
(ratios) of patients achieving certain outcomes was compared 
between the groups by Chi-square test/fisher’s exact test.
RESULTS
A total of 117 patients recruited in the study and out of these 
55 were assigned to receive ORS+racecadotril+zinc and 62 to 
receive only ORS+zinc. Of these, one patient turned out to be 
seropositive for HIV so was excluded from the study. One patient 
in the study group and two from control group withdrew in view 
of persistent vomiting. Hence, the efficacy criteria were assessed 
in total 113 patients, out of which 53 (female=28) patients were 
assigned to study and 60 (female=25) patients to control group. 
Baseline characteristics are given in Table 1.
A significant difference in stool frequency in 48 h between the 
two groups was observed (Table 2). The mean 48 h stool frequency 
in study and control group was 10.47±3.2 and 15.87±4.6 episodes, 
respectively, indicating a significant reduction of 34.1% with the 
use of racecadotril (p=0.00016). A significant reduction of 25.6% 
in the time for recovery was also seen in the study group, and the 
mean time for recovery was 37.98±6.1 and 51.02±9.4 h in the 
study and control group, respectively, (p=0.002).
The mean volume of ORS consumed before recovery in the 
study group was significantly lesser (30.1%) than that in control 
group (162.72±52.65 ml vs. 232.68±39.86 ml). No significant 
difference in the number of patients who required IV fluids 
between two groups was seen and 3 from the study and 7 patients 
from control group required intravenous fluid therapy due to 
worsening of diarrhea. No significant difference in response rate 
was seen between two groups (94.03% vs. 88.03%).
We also observed the difference in the time of recovery 
between the two groups and more number of patients in the study 
group responded in first 24 h as depicted in Table 3.
No significant differences between the groups in the adverse 
events reported. A total of 6 patients from control and 5 from 
study group had serum K+ values <3.5 mmol/L, but none in both 
the groups had any ECG changes or symptoms and all recovered 
without any treatment and had normal serum K+ when repeated 
after 24 h.
DISCUSSION
The results of this study support the efficacy of racecadotril as an 
adjunct to ORT and early continued feeding in infants and children 
with acute watery diarrhea. Patients who received racecadotril had 
a substantial reduction in stool frequency (34.1%), total amount 
of ORS consumed (30.1%), and the time taken for recovery 
(25.6%). The rapidity of effect on stool frequency was shown by 
the fact that a significant difference was seen within first 24 h of 
treatment.
Salazar-Lindo et al. had compared the duration of diarrhea 
in racecadotril and placebo groups according to their rotavirus 
status, and they found that median duration of diarrhea in 
racecadotril group was 28 h regardless of rotavirus status and that 
of placebo was 72 and 52 h, respectively, for rotavirus positive 
and negative children [5]. Cezard et al. compared the duration 
of diarrhea in rotavirus-positive patients and found that 50% of 
patients on racecadotril had recovered in 6.9 h as compared to 
36 h in the placebo group [8]. Baumer et al. in their study on 
200 patients with acute watery diarrhea had found that mean 
duration of diarrhea was 22.8% less in racecadotril group (3.4 vs. 
4.4 days) than the control group [9].
The total amount of ORS consumed in our study was 
162.72 ml in racecadotril group which was 30.1% less than 
the control group. Salazar-Lindo et al. had documented 35.4% 
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reduction in the consumption of ORS with racecadotril [5]. Alam 
et al. studied the role of racecadotril in cholera in adults and found 
no significant difference in ORS consumption between the two 
groups; however, mean stool frequency in 48 h was reduced by 
34.1% with racecadotril (10.47 vs. 15.87 episodes) [10]. Cezard 
et al. had found 50% reduction in the stool output in 48 h in 
children receiving racecadotril when compared to placebo [8].
Salazar-Lindo et al. noted 46% reduction in 48 h stool output 
(157 vs. 331 g/kg) with racecadotril [5] Cojocaru et al. also found 
significantly lower number of stools and faster recovery with 
racecadotril [11].
Three of 53 cases and seven of 60 controls required IV fluid 
therapy. Other authors also had a similar experience in their 
study [8-10].Salazar-Lindo et al. reported that overall 5-day cure 
rate was 84% with racecadotril and 66% with placebo. There 
were no significant adverse effects in both the groups in our study, 
and none of the 11 children with serum potassium value <3.5 
mmol/l had any ECG changes or clinical symptoms. In a study by 
Salazar-Lindo et al., one from racecadotril and two patients from 
control group had persistent vomiting without hypokalemia [5]. 
Cezard et al. reported that 7 from racecadotril and 3 from placebo 
group had vomiting but none had hypokalemia [8].Alam et al. 
reported no difference in the incidence of vomiting, reappearance 
of dehydration, abdominal pain, and headache or anorexia 
between racecadotril and placebo group [10].
On the contrary to the mentioned studies, Santos et al. found 
that the use of racecadotril did not improve the symptoms 
of diarrhea compared with standard ORT in children with 
gastroenteritis in an outpatient setting [12]. Still, most of the 
studies support the beneficial effects of racecadrotil in children 
with acute diarrhea including a recent meta-analysis. Lehert et al. 
conducted a meta-analysis on 9 randomized controlled trials 
to assess the efficacy of racecadrotil as an adjunct to ORS in 
childhood acute gastroenteritis [13]. Authors concluded that as 
an adjunct to ORS, racecadotril has a clinically relevant effect 
in reducing diarrhea (duration, stool output, and stool number), 
irrespective of baseline conditions (dehydration and rotavirus 
or age), treatment conditions (inpatient or outpatient studies) or 
cultural environment [13].
Whenever a patient of acute watery diarrhea is admitted to 
the pediatric ward, the hospital stay and bed occupancy rate 
is increased. Once the child is admitted, until the frequency 
of passage of loose stools is diminished, consistency of stool 
improves, and vomiting is controlled the parents are reluctant 
to take their child home in spite of good advice on home 
management of diarrhea. In this study, it was observed that 26.4% 
of patients on racecadotril had recovered within 24 h as compared 
to 7.2% of ORS group, so hospitals with pediatric units who have 
to deal with large number of diarrhea cases can adopt the policy 
of supplementing racecadotril as an adjunct to ORS to reduce the 
hospital stay of patients. It can be of some help in current health 
economics norm of cost versus benefit analysis.
However, as the sample size was small, it may not be 
possible to document the benefit of this drug to an extent and 
in a manner for a routine recommendation as a drug of choice 
Table 1: Baseline characteristics of study population
Variables Control group Study group Unpaired t-test
N Mean±SD N Mean±SD t p
Body weight (Kg) 60 9.65±4.58 53 10.72±4.53 −1.250 0.214*
Age (months) 60 24.35±20.08 53 31.13±21.48 −1.734 0.086*
Diarrhea before recruitment
Duration (days) 60 2.40±1.62 53 1.87±1.19 2.668 0.061*
Frequency (episodes) 60 7.22±3.23 53 7.09±4.12 0.177 0.860*
Vomiting before recruitment
Duration (days) 40 1.80±1.16 38 1.68±1.21 0.432 0.667*
Frequency (episodes) 40 3.75±2.05 38 4.21±2.98 −0.799 0.427*
SD: Standard deviation, * Not significant
Table 3: Time of recovery in two groups
Time of recovery
(h)
Number (%) Total
Control group Study group
6 to 12 3 (5.40) 5 (9.40) 8 (7.30)
>12 to 24 1 (1.80) 9 (17.00) 10 (9.20)
>24 to 48 30 (53.60) 28 (52.80) 58 (53.20)
>48 22 (39.30) 11 (20.80) 33 (30.30)
Total 56 (100.00) 53 (100.00) 109 (100.00)
Table 2: Comparison of outcome variables in two groups
Variables Control group mean±standard 
deviation
Study group mean±standard 
deviation
% reduction Unpaired t test
(n=60) (n=53) t p
48 h stool frequency 15.87±4.6 10.47±3.2 34.1 7.152 0.00016*
Time for recovery (hour) 51.02±9.4 37.98±6.1 25.6 8.620 0.00012*
ORS consumed (ml) 232.68±52.65 162.72±39.86 30.1 7.881 0.0001*
ORS: Oral rehydration solution, *p<0.05 - Significant
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for the management of acute watery diarrhea. This study was not 
powered for assessing the mortality or number of complications, 
so, larger trials are also needed to detect a significant difference in 
diarrheal duration and its morbidity in different types and severity 
of diarrhea. The scientific evidence shown in this trial may not be 
the total evidence and use of antisecretory drugs like racecadotril 
should await more evidence from well-designed randomized 
controlled studies.
CONCLUSION
Racecadotril is effective as an adjunct to ORT and early continued 
feeding in infants and children with acute watery diarrhea.
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